191 related articles for article (PubMed ID: 37729870)
1. A blood-based metabolomic signature predictive of risk for pancreatic cancer.
Irajizad E; Kenney A; Tang T; Vykoukal J; Wu R; Murage E; Dennison JB; Sans M; Long JP; Loftus M; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger JM; Maitra A; Do KA; Yu B; Wolpin BM; Hanash S; Fahrmann JF
Cell Rep Med; 2023 Sep; 4(9):101194. PubMed ID: 37729870
[TBL] [Abstract][Full Text] [Related]
2. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
Honda K; Katzke VA; Hüsing A; Okaya S; Shoji H; Onidani K; Olsen A; Tjønneland A; Overvad K; Weiderpass E; Vineis P; Muller D; Tsilidis K; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Aleksandrova K; Boeing H; Bueno-de-Mesquita HB; Peeters PH; Trichopoulou A; Lagiou P; Khaw KT; Wareham N; Travis RC; Merino S; Duell EJ; Rodríguez-Barranco M; Chirlaque MD; Barricarte A; Rebours V; Boutron-Ruault MC; Romana Mancini F; Brennan P; Scelo G; Manjer J; Sund M; Öhlund D; Canzian F; Kaaks R
Int J Cancer; 2019 Apr; 144(8):1877-1887. PubMed ID: 30259989
[TBL] [Abstract][Full Text] [Related]
4. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Nolen BM; Brand RE; Prosser D; Velikokhatnaya L; Allen PJ; Zeh HJ; Grizzle WE; Huang Y; Lomakin A; Lokshin AE
PLoS One; 2014; 9(4):e94928. PubMed ID: 24747429
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
6. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.
Boyd LNC; Ali M; Comandatore A; Garajova I; Kam L; Puik JR; Fraga Rodrigues SM; Meijer LL; Le Large TYS; Besselink MG; Morelli L; Frampton A; van Laarhoven HWM; Giovannetti E; Kazemier G
JAMA Netw Open; 2023 Aug; 6(8):e2331197. PubMed ID: 37639271
[TBL] [Abstract][Full Text] [Related]
7. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
8. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive biomarkers for early diagnosis of pancreatic cancer risk: metabolite genomewide association study based on the KCPS-II cohort.
Han Y; Jung KJ; Kim U; Jeon CI; Lee K; Jee SH
J Transl Med; 2023 Dec; 21(1):878. PubMed ID: 38049855
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics study reveals systematic metabolic dysregulation and early detection markers associated with incident pancreatic cancer.
Wang S; Li M; Yan L; He M; Lin H; Xu Y; Wan Q; Qin G; Chen G; Xu M; Wang G; Qin Y; Luo Z; Tang X; Wang T; Zhao Z; Xu Y; Chen Y; Huo Y; Hu R; Ye Z; Dai M; Shi L; Gao Z; Su Q; Mu Y; Zhao J; Chen L; Zeng T; Yu X; Li Q; Shen F; Chen L; Zhang Y; Wang Y; Deng H; Liu C; Wu S; Yang T; Li D; Ning G; Wu T; Wang W; Bi Y; Lu J;
Int J Cancer; 2022 Apr; 150(7):1091-1100. PubMed ID: 34792202
[TBL] [Abstract][Full Text] [Related]
11. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer.
León-Letelier RA; Dou R; Vykoukal J; Yip-Schneider MT; Maitra A; Irajizad E; Wu R; Dennison JB; Do KA; Zhang J; Schmidt CM; Hanash S; Fahrmann JF
Clin Chem; 2024 Jan; 70(1):102-115. PubMed ID: 38175578
[TBL] [Abstract][Full Text] [Related]
12. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer.
Padoan A; Seraglia R; Basso D; Fogar P; Sperti C; Moz S; Greco E; Marchet A; de Manzoni G; Zambon CF; Navaglia F; Cristadoro L; Di Chiara A; Nitti D; Pedrazzoli S; Pavanello G; Plebani M
Pancreas; 2013 May; 42(4):622-32. PubMed ID: 23271396
[TBL] [Abstract][Full Text] [Related]
14. Prospective metabolomics study identifies potential novel blood metabolites associated with pancreatic cancer risk.
Shu X; Zheng W; Yu D; Li HL; Lan Q; Yang G; Cai H; Ma X; Rothman N; Gao YT; Jia W; Xiang YB; Shu XO
Int J Cancer; 2018 Nov; 143(9):2161-2167. PubMed ID: 29717485
[TBL] [Abstract][Full Text] [Related]
15. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
18. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
19. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
20. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
